Song Wang

Song Wang

Auto-generated profile, based on publicly available information

Song Wang

Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNing Huang
Ning Huang
YXYuqing Xia
Yuqing Xia
DZDonghui Zhang
Donghui Zhang
SWSong Wang
Song Wang
YBYitian Bao
Yitian Bao
JCJianguo Che
Jianguo Che
In animal cells, the centrosome is the main microtubule-organizing centre where microtubules are nucleated and anchored. The centriole subdistal appendages (SDAs) are the key structures that anchor microtubules in interphase cells, but the composition and assembly mechanisms of SDAs are not well understood. Here, we reveal that centrosome-binding proteins, coiled-coil domain containing (CCDC) 120 and CCDC68 are two novel SDA components required for hierarchical SDA assembly in human cells. CCDC120 is anchored to SDAs by ODF2 and recruits CEP170 and Ninein to the centrosome through different coiled-coil domains at its N terminus. CCDC68 is a CEP170-interacting protein that competes with CCDC120 in recruiting CEP170 to SDAs. Furthermore, CCDC120 and CCDC68 are required for centrosome microtubule anchoring. Our findings elucidate the molecular basis for centriole SDA hierarchical assembly and microtubule anchoring in human interphase cells.

30 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNing Huang
Ning Huang
DZDonghui Zhang
Donghui Zhang
FLFangyuan Li
Fangyuan Li
PCPeiyuan Chai
Peiyuan Chai
SWSong Wang
Song Wang
JCJianguo Che
Jianguo Che
The primary cilium is elongated from the mother centriole and has diverse signaling roles during development and disease. The CP110-CEP97 complex functions as a negative regulator of ciliogenesis, although the mechanisms regulating its mother centriole localization are poorly understood. Here we show that M-Phase Phosphoprotein 9 (MPP9) is recruited by Kinesin Family Member 24 (KIF24) to the distal end of mother centriole where it forms a ring-like structure and recruits CP110-CEP97 by directly binding CEP97. Loss of MPP9 causes abnormal primary cilia formation in growing cells and mouse kidneys. After phosphorylation by Tau Tubulin Kinase 2 (TTBK2) at the beginning of ciliogenesis, MPP9 is targeted for degradation via the ubiquitin-proteasome system, which facilitates the removal of CP110 and CEP97 from the distal end of the mother centriole. Thus, MPP9 acts as a regulator of ciliogenesis by regulating the localization of CP110-CEP97 at the mother centriole.

1 May 2020 in Insect Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
NHNhan Huynh
Nhan Huynh
SWSong Wang
Song Wang
KKKirst King-Jones
Kirst King-Jones

25 April 2024 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
YSYi Sun
Yi Sun
SQShilei Qin
Shilei Qin
SWSong Wang
Song Wang
JPJiaohui Pang
Jiaohui Pang
QOQiuxiang Ou
Qiuxiang Ou
HZHai Zhong
Hai Zhong
Pulmonary spindle cell carcinoma (PSCC) is a rare and aggressive non‐small cell lung cancer (NSCLC) subtype with a dismal prognosis. The molecular characteristics of PSCC are largely unknown due to its rarity, which limits the diagnosis and treatment of this historically poorly characterized malignancy. We present comprehensive genomic profiling results of baseline tumor samples from 22 patients histologically diagnosed with PSCC, representing the largest cohort to date. Somatic genetic variant detection was compared between paired plasma samples and primary tumors from 13 patients within our cohort. The associations among genomic features, treatment, and prognosis were also analyzed in representative patient cases. TP53 (54.5%), TERT (36.4%), CDKN2A (27.3%), and MET (22.7%) were most frequently mutated. Notably, 81.8% of patients had actionable targets in their baseline tumors, including MET (22.7%), ERBB2 (13.6%), EGFR (9.1%), KRAS (9.1%), ALK (9.1%), and ROS1 (4.5%). The median tumor mutation burden (TMB) for PSCC tumors was 5.5 mutations per megabase (muts/Mb). TMB‐high tumors (>10 muts/Mb) exhibited a significantly higher mutation frequency in genes such as KRAS, ARID2, FOXL2, and LRP1B, as well as within the DNA mismatch repair pathway. The detection rates for single nucleotide variants and structural variants were comparable between matched tumor and plasma samples, with 48.6% of genetic variants being mutually identified in both sample types. Additionally, a patient with a high mutation load and positive PD‐L1 expression demonstrated a 7‐month survival benefit from chemoimmunotherapy. Furthermore, a patient with an ALK‐rearranged tumor achieved a remarkable 3‐year progression‐free survival following crizotinib treatment. Overall, our findings deepen the understanding of the complex genomic landscape of PSCC, revealing actionable targets amenable to tailored treatment of this poorly characterized malignancy.

14 October 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YCYulong Chen
Yulong Chen
YSYanjun Su
Yanjun Su
RZRan Zhang
Ran Zhang
SWSong Wang
Song Wang
JZJiangyan Zhang
Jiangyan Zhang
JYJian You
Jian You
Neoadjuvant chemo-immunotherapy (NCIT) aims to improve surgical and survival outcomes of non-small cell lung cancer (NSCLC) patients. However, the clinical application of NCIT still necessitates coordinated immune and molecular biomarker testing. We conducted whole transcriptome sequencing on baseline and surgical samples from 26 patients with stage II–III resectable NSCLC who underwent neoadjuvant pembrolizumab plus chemotherapy followed by surgery. Gene expression and immune cell characteristics in the tumor microenvironment were assessed in relation to pathological complete response (pCR) and patient prognosis. Baseline pCR tumors were characterized by increased expression of genes related to antigen presentation (HLA-C, HLA-E, B2M), immune checkpoint regulation (BTN3A1, CD274), and innate immunity (HMGB1). Surgical samples from pCR patients showed elevated expression of immune-related genes (IGHD, LILRA6, and ICOSLG) but reduced CEACAM6 expression linked to cell adhesion and tumor progression. During NCIT, plasma cells and resting NK cells declined consistently across pathological groups. Non-pCR patients exhibited greater leukocyte-mediated immunity and higher CD8 + T cell infiltration (P < 0.01) post-treatment, suggestive of a sustained anti-tumor immune response. Baseline MGAT5B expression predicted pathological response (area under the curve: 0.86) and was associated with shorter disease-free survival (DFS; P = 0.03), with a consistent trend for overall survival (OS). Higher CEACAM6 expression in surgical samples was associated with both shorter DFS and OS (P = 0.03 and P = 0.04, respectively). The clinical relevance of MGAT5B and CEACAM6 expression for predicting NCIT response and prognosis was further validated in a clinical validation cohort. Our study identified molecular biomarkers for pathological and survival outcomes, which may inform optimal treatment decision-making, guide postoperative therapy, and improve survival outcomes for stage II–III patients with resectable NSCLC.

9 September 2026 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
YMYakui Mou
Yakui Mou
HFHan Fang
Han Fang
WZWenbin Zhang
Wenbin Zhang
SWSong Wang
Song Wang
HZHua Zhang
Hua Zhang
XSXicheng Song
Xicheng Song
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at advanced stages, highlighting the need for accurate, non-invasive detection strategies. In the DECIPHER-HNSC study, we developed an ensemble machine learning model integrating multi-dimensional cell-free DNA (cfDNA) fragmentomic features, including focal copy number variation, fragment size profile, and genome-wide methylation. The model was trained on 144 HNSCC patients and 148 healthy controls, and its performance was validated in two independent cohorts (internal, n = 196; external, n = 193). Through validation, it achieved an area under the curve (AUC) of 0.962 (95% CI: 0.937–0.987) in the internal cohort and 0.966 (95% CI: 0.943–0.989) in the external cohort. At 95% specificity, it yielded sensitivities of 78.0% and 81.1%, respectively, and demonstrated consistent performance across clinical subgroups. Fragmentomic profiles were associated with tumor aggressiveness, and higher prediction scores independently predicted shorter overall survival after adjustment for key clinical covariates, whether modeled using the diagnostic cutoff or as a continuous variable. These findings establish artificial intelligence (AI)-driven cfDNA fragmentomics as a promising approach for early detection and risk stratification in HNSCC, offering potential to advance precision medicine.